| Oxidation of LDL and its clinical implication. | |
| | |
MedLine Citation:
|
PMID: 18625445 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Oxidative modification of low-density lipoprotein (LDL) is one of the earliest events in atherosclerosis. Oxidized LDL (oxLDL) represents a variety of modification of both lipid and apolipoprotein B (apoB) components by lipid peroxidation. This promotes atherosclerosis through inflammatory and immunologic mechanisms that lead to the formation of macrophage foam cells. Recent findings also suggest that oxLDL forms complexes with beta(2)-glycoprotein I (beta(2)GPI) and/or C-reactive protein (CRP) within atherosclerotic lesions and that these complexes appear in the circulation. Autoantibodies (auto-Abs) against oxLDL/beta(2)GPI complexes occur in patients with systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS). These autoantibodies significantly correlate with arterial thrombosis. IgG auto-Abs having similar specificity emerge spontaneously in NZWxBXSB F1 mice, which generally are considered to be an animal model of APS, and these mice produce a monoclonal IgG auto-Ab (WB-CAL-1) against oxLDL/beta(2)GPI complexes. WB-CAL-1 significantly increased the in vitro uptake of oxLDL/beta(2)GPI complexes by macrophages, which suggests that such IgG auto-Abs are pro-atherogenic. In contrast, IgM anti-oxLDL natural Abs found in the atherosclerosis-prone mice have been proposed to be protective. The presence of such Abs in humans has been documented in many publications but their exact pathophysiological significance remains unclear. In this article, we review recent progress in our understanding of the clinical significance of oxidation of LDL, formation of oxLDL complexes, and Abs in atherosclerotic and/or autoimmune disease. |
| | |
Authors:
|
Eiji Matsuura; Graham R V Hughes; Munther A Khamashta |
Related Documents
:
|
9284075 - Motor and cognitive deficits in apolipoprotein e-deficient mice after closed head injury. 16712825 - Thiol compounds metabolism in mice, rats and humans: comparative study and potential ex... 19808545 - Development of receptor for advanced glycation end products-directed imaging of atheros... 18356775 - Atherosclerosis and vascular calcification in uraemia - a new experimental model. 18322305 - Co-administration of cpg oligonucleotides and chenopodium album extract reverse igg2a/i... 16861655 - Role of transcription factor t-bet expression by cd4+ cells in gastritis due to helicob... |
Publication Detail:
|
Type: Journal Article; Review Date: 2008-05-12 |
Journal Detail:
|
Title: Autoimmunity reviews Volume: 7 ISSN: 1568-9972 ISO Abbreviation: Autoimmun Rev Publication Date: 2008 Jul |
Date Detail:
|
Created Date: 2008-07-15 Completed Date: 2008-09-11 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101128967 Medline TA: Autoimmun Rev Country: Netherlands |
Other Details:
|
Languages: eng Pagination: 558-66 Citation Subset: IM |
Affiliation:
|
Department of Cell Chemistry, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan, 2-5-1 Shikata-cho, Okayama 700-8558, Japan. eijimatu@med.okayama-u.ac.jp |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Animals Atherosclerosis / immunology* Autoantibodies / blood, immunology Autoimmune Diseases / immunology* C-Reactive Protein / metabolism Humans Lipoproteins, LDL / blood*, chemistry, immunology Mice beta 2-Glycoprotein I / blood, immunology |
| Chemical | |
Reg. No./Substance:
|
0/Autoantibodies; 0/Lipoproteins, LDL; 0/beta 2-Glycoprotein I; 0/oxidized low density lipoprotein; 9007-41-4/C-Reactive Protein |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Autoimmune mechanisms in type 1 diabetes.
Next Document: Autoimmunity and oxidatively modified autoantigens.